Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives.

ABSTRACT: Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer such as serous, clear cell, and carcinosarcoma, shows advanced/recurrent disease and dismal prognosis. Novel therapeutic development is required for patients with aggressive endometrial cancers. Recent genomic and immunohistochemical analyses revealed human epidermal growth factor receptor 2 (HER2) overexpression/gene amplification in 20%-40% of patients with type II endometrial cancer. Historically, HER2 targeted therapy has been developed for various major canc

SUBMITTER: Saito A 

PROVIDER: S-EPMC8546653 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature